In one paragraphArticle in Nature immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
16 authors.
Natália G SampaioMedical Research Council Translational Immune Discovery Unit, Medical Research Council Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK. natalia.sampaio@hudson.org.au.ORCID http://orcid.org/0000-0002-8396-1354 Tanja DavisMedical Research Council Translational Immune Discovery Unit, Medical Research Council Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Antonio G Dias Junior *Medical Research Council Translational Immune Discovery Unit, Medical Research Council Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0003-4392-4206 Lise ChauveauRNA viruses and metabolism team, Institut de Recherche en Infectiologie de Montpellier (IRIM), CNRS, University of Montpellier, Montpellier, France.
Georgie Wray-McCannCentre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia.
Valerie OdonMedical Research Council Translational Immune Discovery Unit, Medical Research Council Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Vladyslava LiudkovskaIMol Polish Academy of Sciences, Warsaw, Poland.
Chiara CursiMedical Research Council Translational Immune Discovery Unit, Medical Research Council Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Alice MayerMedical Research Council Translational Immune Discovery Unit, Medical Research Council Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-6859-0612 Madara RatnadiwakaraDepartment of Molecular and Translational Sciences, School of Clinical Sciences, Monash University, Clayton, Victoria, Australia.
Minna-Liisa ÄnköDepartment of Molecular and Translational Sciences, School of Clinical Sciences, Monash University, Clayton, Victoria, Australia.
Jan RehwinkelMedical Research Council Translational Immune Discovery Unit, Medical Research Council Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0003-3841-835X Funding
Department of Health | National Health and Medical Research Council (NHMRC) 2035500RCUK | Medical Research Council (MRC) MC_UU_00008RCUK | Medical Research Council (MRC) MR/Y013212/1Wellcome TrustWellcome Trust (Wellcome) 100954/Z/13/Z
6 · The paper itselfAbstract
MDA5 is an innate immune RNA sensor that senses infection with a range of viruses and other pathogens. MDA5's RNA agonists are not well defined. Here we used single-nucleotide resolution crosslinking and immunoprecipitation (iCLIP) to study its ligands. Of note, upon infection with SARS-CoV-2 or encephalomyocarditis virus, MDA5 bound overwhelmingly to cellular RNAs. Many binding sites were intronic and proximal to Alu elements and to potentially base-paired structures. Concomitantly, cytoplasmic levels of aberrant transcripts and intron-containing unspliced transcripts increased in infected cells and displayed enrichment of MDA5 iCLIP peaks. Moreover, overexpression of the splicing factor SRSF3 reduced aberrant transcription and abrogated MDA5 activation. Taken together, we propose that MDA5 surveys RNA processing fidelity and can detect infections by sensing perturbations of post-transcriptional events such as splicing.
Indexed as
Cardiovirus InfectionsEncephalomyocarditis virusInterferon-Induced Helicase, IFIH1RNASARS-CoV-2Alu ElementsAnimalsHEK293 CellsHomeostasisHumansImmunity, InnateInnate Immunity RecognitionRNA SplicingSerine-Arginine Splicing FactorsIFIH1 protein, humanInterferon-Induced Helicase, IFIH1RNASerine-Arginine Splicing FactorsSRSF3 protein, human
Identifiers
PMID42581186
PMCPMC13506345
What OpenQuestion holds
Textmetadata
Read underepoch 390